Skip to main content
SpringerLink
Log in

High-Sensitivity C-Reactive Protein

  • Chapter
  • First Online:
Cardiovascular Risk Assessment in Primary Prevention

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 806 Accesses

Abstract

The development of atherosclerotic cardiovascular disease (ASCVD) is multifactorial and depends on the plasma concentration of lipids and mediators of inflammation. As the most common inflammatory biomarker used in the assessment of atherosclerotic cardiovascular disease risk, high-sensitivity C-reactive protein (hsCRP) has been shown to independently predict future cardiovascular events. As a risk enhancer in primary prevention, it can help guide decision-making around statin use; in secondary prevention, it can help identify residual inflammatory risk among those treated with optimal medical therapy. While many anti-inflammatory therapies have the potential to reduce cardiovascular risk, incorporation into routine clinical practice will depend on additional data related to efficacy, safety, and cost-effectiveness. Until then, statin therapy remains the first-line treatment for the reduction of atherosclerotic cardiovascular disease risk in primary and secondary prevention.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GG, Van Tassell BW, Robati R, Roach LM, Arena RA, Roberts CS, Varma A, Gelwix CC, Salloum FN, Hastillo A, Dinarello CA, Vetrovec GW, VCU-ART Investigators. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol. 2010;105(10):1371–1377.e1. https://doi.org/10.1016/j.amjcard.2009.12.059.

    Article  CAS  PubMed  Google Scholar 

  • Abbate A, Van Tassell BW, Biondi-Zoccai G, Kontos MC, Grizzard JD, Spillman DW, Oddi C, Roberts CS, Melchior RD, Mueller GH, Abouzaki NA, Rengel LR, Varma A, Gambill ML, Falcao RA, Voelkel NF, Dinarello CA, Vetrovec GW. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol. 2013;111(10):1394–400. https://doi.org/10.1016/j.amjcard.2013.01.287.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Aguilar D, Fisher MR, O’Connor CM, Dunne MW, Muhlestein JB, Yao L, Gupta S, Benner RJ, Cook TD, Edwards D, Pfeffer MA. Investigators in the weekly intervention with zithromax for atherosclerosis and its related disorder study. Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease. Am Heart J. 2006;152(2):298–304. https://doi.org/10.1016/j.ahj.2005.11.011.

    Article  CAS  PubMed  Google Scholar 

  • Albert MA, Danielson E, Rifai N, Ridker PM, PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286(1):64–70. https://doi.org/10.1001/jama.286.1.64.

    Article  CAS  PubMed  Google Scholar 

  • Albert MA, Glynn RJ, Buring J, Ridker PM. C-reactive protein levels among women of various ethnic groups living in the United States (from the Women’s Health Study). Am J Cardiol. 2004;93(10):1238–42. https://doi.org/10.1016/j.amjcard.2004.01.067.

    Article  CAS  PubMed  Google Scholar 

  • Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019;140(11):e596–646. https://doi.org/10.1161/CIR.0000000000000678. Erratum in: Circulation. 2019;140(11):e649-e650. Erratum in: Circulation. 2020;141(4):e60. Erratum in: Circulation. 2020;141(16):e774.

    Article  PubMed  PubMed Central  Google Scholar 

  • Arroyo-Espliguero R, Avanzas P, Quiles J, Kaski JC. Predictive value of coronary artery stenoses and C-reactive protein levels in patients with stable coronary artery disease. Atherosclerosis. 2009;204(1):239–43. https://doi.org/10.1016/j.atherosclerosis.2008.08.009.

    Article  CAS  PubMed  Google Scholar 

  • Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78. https://doi.org/10.1016/S0140-6736(05)67394-1. Erratum in: Lancet. 2005;366(9494):1358. Erratum in: Lancet. 2008;371(9630):2084

    Article  CAS  PubMed  Google Scholar 

  • Blaha MJ, Budoff MJ, DeFilippis AP, Blankstein R, Rivera JJ, Agatston A, O’Leary DH, Lima J, Blumenthal RS, Nasir K. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. Lancet. 2011;378(9792):684–92. https://doi.org/10.1016/S0140-6736(11)60784-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Blake GJ, Ridker PM. C-reactive protein and prognosis after percutaneous coronary intervention. Eur Heart J. 2002;23(12):923–5. https://doi.org/10.1053/euhj.2001.3130.

    Article  CAS  PubMed  Google Scholar 

  • Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, Tershakovec AM, Blazing MA, Braunwald E. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation. 2015;132(13):1224–33. https://doi.org/10.1161/CIRCULATIONAHA.115.018381.

    Article  CAS  PubMed  Google Scholar 

  • Bohula EA, Giugliano RP, Leiter LA, Verma S, Park JG, Sever PS, Lira Pineda A, Honarpour N, Wang H, Murphy SA, Keech A, Pedersen TR, Sabatine MS. Inflammatory and cholesterol risk in the FOURIER trial. Circulation. 2018;138(2):131–40. https://doi.org/10.1161/CIRCULATIONAHA.118.034032.

    Article  CAS  PubMed  Google Scholar 

  • Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151(7):483–95. https://doi.org/10.7326/0003-4819-151-7-200910060-00009.

    Article  PubMed  Google Scholar 

  • Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM, IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–97. https://doi.org/10.1056/NEJMoa1410489.

    Article  CAS  PubMed  Google Scholar 

  • Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359(9313):1173–7. https://doi.org/10.1016/S0140-6736(02)08213-2.

    Article  CAS  PubMed  Google Scholar 

  • Clark CR, Coull B, Berkman LF, Buring JE, Ridker PM. Geographic variation in cardiovascular inflammation among healthy women in the Women’s Health Study. PLoS One. 2011;6(11):e27468. https://doi.org/10.1371/journal.pone.0027468.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cook NR. Comments on ‘Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond’ by M. J. Pencina et al., Statistics in Medicine (DOI: 10.1002/sim.2929). Stat Med. 2008;27(2):191–5. https://doi.org/10.1002/sim.2987.

    Article  PubMed  Google Scholar 

  • Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med. 2009;150(11):795–802. https://doi.org/10.7326/0003-4819-150-11-200906020-00007.

    Article  PubMed  PubMed Central  Google Scholar 

  • Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med. 2006;145(1):21–9. https://doi.org/10.7326/0003-4819-145-1-200607040-00128.

    Article  CAS  PubMed  Google Scholar 

  • Cook NR, Paynter NP, Eaton CB, Manson JE, Martin LW, Robinson JG, Rossouw JE, Wassertheil-Smoller S, Ridker PM. Comparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women’s Health Initiative. Circulation. 2012;125(14):1748–56., S1-11. https://doi.org/10.1161/CIRCULATIONAHA.111.075929.

    Article  PubMed  PubMed Central  Google Scholar 

  • Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321(7255):199–204. https://doi.org/10.1136/bmj.321.7255.199.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • DeFilippis AP, Blaha MJ, Ndumele CE, Budoff MJ, Lloyd-Jones DM, McClelland RL, Lakoski SG, Cushman M, Wong ND, Blumenthal RS, Lima J, Nasir K. The association of Framingham and Reynolds risk scores with incidence and progression of coronary artery calcification in MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2011;58(20):2076–83. https://doi.org/10.1016/j.jacc.2011.08.022.

    Article  PubMed  PubMed Central  Google Scholar 

  • Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615–22. https://doi.org/10.1001/jama.279.20.1615.

    Article  CAS  PubMed  Google Scholar 

  • Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132–40. https://doi.org/10.1016/S0140-6736(09)61717-7.

    Article  CAS  Google Scholar 

  • Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M, Butterworth AS, Amouyel P, Assmann G, Bakker SJ, Barr EL, Barrett-Connor E, Benjamin EJ, Björkelund C, Brenner H, Brunner E, Clarke R, Cooper JA, Cremer P, Cushman M, Dagenais GR, D’Agostino RB Sr, Dankner R, Davey-Smith G, Deeg D, Dekker JM, Engström G, Folsom AR, Fowkes FG, Gallacher J, Gaziano JM, Giampaoli S, Gillum RF, Hofman A, Howard BV, Ingelsson E, Iso H, Jørgensen T, Kiechl S, Kitamura A, Kiyohara Y, Koenig W, Kromhout D, Kuller LH, Lawlor DA, Meade TW, Nissinen A, Nordestgaard BG, Onat A, Panagiotakos DB, Psaty BM, Rodriguez B, Rosengren A, Salomaa V, Kauhanen J, Salonen JT, Shaffer JA, Shea S, Ford I, Stehouwer CD, Strandberg TE, Tipping RW, Tosetto A, Wassertheil-Smoller S, Wennberg P, Westendorp RG, Whincup PH, Wilhelmsen L, Woodward M, Lowe GD, Wareham NJ, Khaw KT, Sattar N, Packard CJ, Gudnason V, Ridker PM, Pepys MB, Thompson SG, Danesh J. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367(14):1310–20. https://doi.org/10.1056/NEJMoa1107477.

    Article  Google Scholar 

  • Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, Couture P, Dufour R, Fodor G, Francis GA, Grover S, Gupta M, Hegele RA, Lau DC, Leiter L, Lewis GF, Lonn E, Mancini GB, Ng D, Pearson GJ, Sniderman A, Stone JA, Ur E. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Can J Cardiol. 2009;25(10):567–79. https://doi.org/10.1016/s0828-282x(09)70715-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gilbert J, Lekstrom-Himes J, Donaldson D, Lee Y, Hu M, Xu J, Wyant T, Davidson M, MLN1202 Study Group. Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. Am J Cardiol. 2011;107(6):906–11. https://doi.org/10.1016/j.amjcard.2010.11.005.

    Article  CAS  PubMed  Google Scholar 

  • Giles JT, Sattar N, Gabriel S, Ridker PM, Gay S, Warne C, Musselman D, Brockwell L, Shittu E, Klearman M, Fleming TR. Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol. 2020;72(1):31–40. https://doi.org/10.1002/art.41095.

    Article  CAS  PubMed  Google Scholar 

  • Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O’Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PW, Jordan HS, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49–73. https://doi.org/10.1161/01.cir.0000437741.48606.98. Erratum in: Circulation. 2014;129(25 Suppl 2):S74-5

    Article  PubMed  Google Scholar 

  • Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, Lalwani ND, Patel PM, Zhao X, Duell PB. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial. JAMA. 2019;322(18):1780–8. https://doi.org/10.1001/jama.2019.16585. Erratum in: JAMA. 2020;323(3):282.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Goldfine AB, Fonseca V, Jablonski KA, Chen YD, Tipton L, Staten MA, Shoelson SE, Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2013a;159(1):1–12. https://doi.org/10.7326/0003-4819-159-1-201307020-00003.

    Article  PubMed  PubMed Central  Google Scholar 

  • Goldfine AB, Buck JS, Desouza C, Fonseca V, Chen YD, Shoelson SE, Jablonski KA, Creager MA. TINSAL-FMD (Targeting Inflammation Using Salsalate in Type 2 Diabetes–Flow-Mediated Dilation) Ancillary Study Team. Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). Diabetes Care. 2013b;36(12):4132–9. https://doi.org/10.2337/dc13-0859.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC Jr, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK, Smith SC Jr, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Nishimura R, Ohman EM, Page RL, Stevenson WG, Tarkington LG, Yancy CW, American College of Cardiology Foundation; American Heart Association. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010;56(25):e50–103. https://doi.org/10.1016/j.jacc.2010.09.001.

    Article  PubMed  Google Scholar 

  • Grimaldi-Bensouda L, Alpérovitch A, Aubrun E, Danchin N, Rossignol M, Abenhaim L, Richette P, PGRx MI Group. Impact of allopurinol on risk of myocardial infarction. Ann Rheum Dis. 2015;74(5):836–42. https://doi.org/10.1136/annrheumdis-2012-202972.

    Article  CAS  PubMed  Google Scholar 

  • Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285–350. https://doi.org/10.1016/j.jacc.2018.11.003. Erratum in: J Am Coll Cardiol. 2019;73(24):3237-3241.

    Article  PubMed  Google Scholar 

  • Haidari M, Javadi E, Sadeghi B, Hajilooi M, Ghanbili J. Evaluation of C-reactive protein, a sensitive marker of inflammation, as a risk factor for stable coronary artery disease. Clin Biochem. 2001;34(4):309–15. https://doi.org/10.1016/s0009-9120(01)00227-2.

    Article  CAS  PubMed  Google Scholar 

  • Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6:508–19.

    Article  CAS  Google Scholar 

  • Hauser TH, Salastekar N, Schaefer EJ, Desai T, Goldfine HL, Fowler KM, Weber GM, Welty F, Clouse M, Shoelson SE, Goldfine AB, Targeting Inflammation Using Salsalate in Cardiovascular Disease (TINSAL-CVD) Study Team. Effect of targeting inflammation with salsalate: the TINSAL-CVD randomized clinical trial on progression of coronary plaque in overweight and obese patients using statins. JAMA Cardiol. 2016;1(4):413–23. https://doi.org/10.1001/jamacardio.2016.0605.

    Article  PubMed  Google Scholar 

  • Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997;349(9050):462–6. https://doi.org/10.1016/s0140-6736(96)07591-5.

    Article  CAS  PubMed  Google Scholar 

  • Helfand M, Buckley DI, Freeman M, Fu R, Rogers K, Fleming C, Humphrey LL. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151(7):496–507. https://doi.org/10.7326/0003-4819-151-7-200910060-00010.

    Article  PubMed  Google Scholar 

  • Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go AS, Harrell FE Jr, Hong Y, Howard BV, Howard VJ, Hsue PY, Kramer CM, JP MC, Normand SL, O’Donnell CJ, Smith SC Jr, Wilson PW, American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119(17):2408–16. https://doi.org/10.1161/CIRCULATIONAHA.109.192278.

    Article  PubMed  PubMed Central  Google Scholar 

  • Holte E, Kleveland O, Ueland T, Kunszt G, Bratlie M, Broch K, Michelsen AE, Bendz B, Amundsen BH, Aakhus S, DamÃ¥s JK, Gullestad L, Aukrust P, Wiseth R. Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction. Heart. 2017;103(19):1521–7. https://doi.org/10.1136/heartjnl-2016-310875.

    Article  CAS  PubMed  Google Scholar 

  • Hong YJ, Jeong MH, Lim SY, Lee SR, Hong SN, Kim KH, Sohn IS, Park HW, Kim JH, Kim W, Ahn Y, Cho JG, Park JC, Kang JC. Relation of soft plaque and elevated preprocedural high-sensitivity C-reactive protein levels to incidence of in-stent restenosis after successful coronary artery stenting. Am J Cardiol. 2006;98(3):341–5. https://doi.org/10.1016/j.amjcard.2006.02.037.

    Article  CAS  PubMed  Google Scholar 

  • Horne BD, Muhlestein JB, Carlquist JF, Bair TL, Madsen TE, Hart NI, Anderson JL. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol. 2000;36(6):1774–80. https://doi.org/10.1016/s0735-1097(00)00950-5.

    Article  CAS  PubMed  Google Scholar 

  • Kangasniemi OP, Biancari F, Luukkonen J, Vuorisalo S, Satta J, Pokela R, Juvonen T. Preoperative C-reactive protein is predictive of long-term outcome after coronary artery bypass surgery. Eur J Cardiothorac Surg. 2006;29(6):983–5. https://doi.org/10.1016/j.ejcts.2006.02.022.

    Article  PubMed  Google Scholar 

  • Kaul S, Morrissey RP, Diamond GA. By Jove! What is a clinician to make of JUPITER? Arch Intern Med. 2010;170(12):1073–7. https://doi.org/10.1001/archinternmed.2010.189.

    Article  CAS  PubMed  Google Scholar 

  • Kavousi M, Elias-Smale S, Rutten JH, Leening MJ, Vliegenthart R, Verwoert GC, Krestin GP, Oudkerk M, de Maat MP, Leebeek FW, Mattace-Raso FU, Lindemans J, Hofman A, Steyerberg EW, van der Lugt A, van den Meiracker AH, Witteman JC. Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med. 2012;156(6):438–44. https://doi.org/10.7326/0003-4819-156-6-201203200-00006.

    Article  PubMed  Google Scholar 

  • Kawashiri SY, Kawakami A, Yamasaki S, Imazato T, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, Nakamura H, Ida H, Origuchi T, Ueki Y, Eguchi K. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int. 2011;31(4):451–6. https://doi.org/10.1007/s00296-009-1303-y.

    Article  CAS  PubMed  Google Scholar 

  • Kleveland O, Kunszt G, Bratlie M, Ueland T, Broch K, Holte E, Michelsen AE, Bendz B, Amundsen BH, Espevik T, Aakhus S, DamÃ¥s JK, Aukrust P, Wiseth R, Gullestad L. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur Heart J. 2016;37(30):2406–13. https://doi.org/10.1093/eurheartj/ehw171.

    Article  CAS  PubMed  Google Scholar 

  • Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int J Cardiol. 2013;168(6):5126–34. https://doi.org/10.1016/j.ijcard.2013.07.113.

    Article  PubMed  Google Scholar 

  • Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, Döring A, Hutchinson WL, Pepys MB. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99(2):237–42. https://doi.org/10.1161/01.cir.99.2.237.

    Article  CAS  PubMed  Google Scholar 

  • Lakoski SG, Cushman M, Criqui M, Rundek T, Blumenthal RS, D’Agostino RB Jr, Herrington DM. Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am Heart J. 2006;152(3):593–8. https://doi.org/10.1016/j.ahj.2006.02.015.

    Article  CAS  PubMed  Google Scholar 

  • LaMonte MJ, Durstine JL, Yanowitz FG, Lim T, DuBose KD, Davis P, Ainsworth BE. Cardiorespiratory fitness and C-reactive protein among a tri-ethnic sample of women. Circulation. 2002;106(4):403–6. https://doi.org/10.1161/01.cir.0000025425.20606.69.

    Article  CAS  PubMed  Google Scholar 

  • Lawler PR, Bhatt DL, Godoy LC, Lüscher TF, Bonow RO, Verma S, Ridker PM. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J. 2020:ehaa099. https://doi.org/10.1093/eurheartj/ehaa099. [Epub ahead of print].

  • Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–74. https://doi.org/10.1038/nature01323.

    Article  CAS  PubMed  Google Scholar 

  • Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–43. https://doi.org/10.1161/hc0902.104353.

    Article  CAS  PubMed  Google Scholar 

  • Libby P, Ridker PM, Hansson GK, Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54(23):2129–38. https://doi.org/10.1016/j.jacc.2009.09.009.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994;331(7):417–24. https://doi.org/10.1056/NEJM199408183310701.

    Article  CAS  PubMed  Google Scholar 

  • Lloyd-Jones DM, Liu K, Tian L, Greenland P. Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med. 2006;145(1):35–42. https://doi.org/10.7326/0003-4819-145-1-200607040-00129.

    Article  CAS  PubMed  Google Scholar 

  • Maier W, Altwegg LA, Corti R, Gay S, Hersberger M, Maly FE, Sütsch G, Roffi M, Neidhart M, Eberli FR, Tanner FC, Gobbi S, von Eckardstein A, Lüscher TF. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. Circulation. 2005;111(11):1355–61. https://doi.org/10.1161/01.CIR.0000158479.58589.0A.

    Article  CAS  PubMed  Google Scholar 

  • Martínez GJ, Robertson S, Barraclough J, Xia Q, Mallat Z, Bursill C, Celermajer DS, Patel S. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J Am Heart Assoc. 2015;4(8):e002128. https://doi.org/10.1161/JAHA.115.002128.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Micha R, Imamura F, Wyler von Ballmoos M, Solomon DH, Hernán MA, Ridker PM, Mozaffarian D. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108(9):1362–70. https://doi.org/10.1016/j.amjcard.2011.06.054.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Morrow DA, Rifai N, Antman EM, Weiner DL, CH MC, Cannon CP, Braunwald E. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in myocardial infarction. J Am Coll Cardiol. 1998;31(7):1460–5. https://doi.org/10.1016/s0735-1097(98)00136-3.

    Article  CAS  PubMed  Google Scholar 

  • Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, Rifai N, Califf RM, Braunwald E. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor trial. Circulation. 2006;114(4):281–8. https://doi.org/10.1161/CIRCULATIONAHA.106.628909.

    Article  CAS  PubMed  Google Scholar 

  • Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22) trial. J Am Coll Cardiol. 2009;54(25):2358–62. https://doi.org/10.1016/j.jacc.2009.10.005.

    Article  CAS  PubMed  Google Scholar 

  • Nidorf M, Thompson PL. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol. 2007;99(6):805–7. https://doi.org/10.1016/j.amjcard.2006.10.039.

    Article  CAS  PubMed  Google Scholar 

  • Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404–10. https://doi.org/10.1016/j.jacc.2012.10.027.

    Article  CAS  PubMed  Google Scholar 

  • Nidorf SM, ATL F, Mosterd A, Eikelboom JW, Schut A, TSJ O, SHK T, Xu XF, Ireland MA, Lenderink T, Latchem D, Hoogslag P, Jerzewski A, Nierop P, Whelan A, Hendriks R, Swart H, Schaap J, AFM K, van MWJ H, Saklani P, Tan I, Thompson AG, Morton A, Judkins C, Bax WA, Dirksen M, Alings M, Hankey GJ, Budgeon CA, JGP T, Cornel JH, Thompson PL, LoDoCo2 Trial Investigators. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–47. https://doi.org/10.1056/NEJMoa2021372.

    Article  CAS  PubMed  Google Scholar 

  • Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O’Shaughnessy C, Ganz P, Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352(1):29–38. https://doi.org/10.1056/NEJMoa042000.

    Article  CAS  PubMed  Google Scholar 

  • Pankow JS, Folsom AR, Cushman M, Borecki IB, Hopkins PN, Eckfeldt JH, Tracy RP. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis. 2001;154(3):681–9. https://doi.org/10.1016/s0021-9150(00)00586-4.

    Article  CAS  PubMed  Google Scholar 

  • Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F, Centers for Disease Control and Prevention, American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499–511. https://doi.org/10.1161/01.cir.0000052939.59093.45.

    Article  PubMed  Google Scholar 

  • Pradhan AD, Aday AW, Rose LM, Ridker PM. Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy. Circulation. 2018;138(2):141–9. https://doi.org/10.1161/CIRCULATIONAHA.118.034645.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rana JS, Cote M, Després JP, Sandhu MS, Talmud PJ, Ninio E, Wareham NJ, Kastelein JJ, Zwinderman AH, Khaw KT, Boekholdt SM. Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk prospective population study. Heart. 2009;95(20):1682–7. https://doi.org/10.1136/hrt.2009.170134.

    Article  CAS  PubMed  Google Scholar 

  • Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, Robinson PL, Ballantyne CM, CLEAR Harmony Trial. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022–32. https://doi.org/10.1056/NEJMoa1803917.

    Article  CAS  PubMed  Google Scholar 

  • Rentoukas E, Tsarouhas K, Tsitsimpikou C, Lazaros G, Deftereos S, Vavetsi S. The prognostic impact of allopurinol in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Int J Cardiol. 2010;145(2):257–8. https://doi.org/10.1016/j.ijcard.2009.08.037.

    Article  CAS  PubMed  Google Scholar 

  • Ridker PM. Hyperlipidemia as an instigator of inflammation: inaugurating new approaches to vascular prevention. J Am Heart Assoc. 2012;1(1):3–5. https://doi.org/10.1161/JAHA.112.000497.

    Article  PubMed  PubMed Central  Google Scholar 

  • Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res. 2016a;118(1):145–56. https://doi.org/10.1161/CIRCRESAHA.115.306656.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ridker PM. A test in context: high-sensitivity C-reactive protein. J Am Coll Cardiol. 2016b;67(6):712–23. https://doi.org/10.1016/j.jacc.2015.11.037.

    Article  PubMed  Google Scholar 

  • Ridker PM. Clinician’s guide to reducing inflammation to reduce atherothrombotic risk: JACC review topic of the week. J Am Coll Cardiol. 2018;72(25):3320–31. https://doi.org/10.1016/j.jacc.2018.06.082.

    Article  PubMed  Google Scholar 

  • Ridker PM. From CANTOS to CIRT to COLCOT to clinic: will all atherosclerosis patients soon be treated with combination lipid-lowering and inflammation-inhibiting agents? Circulation. 2020;141(10):787–9. https://doi.org/10.1161/CIRCULATIONAHA.119.045256.

    Article  PubMed  Google Scholar 

  • Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation. 2004;109(16):1955–9. https://doi.org/10.1161/01.CIR.0000125690.80303.A8.

    Article  PubMed  Google Scholar 

  • Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336(14):973–9. https://doi.org/10.1056/NEJM199704033361401. Erratum in: N Engl J Med 1997;337(5):356

    Article  CAS  PubMed  Google Scholar 

  • Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98(9):839–44. https://doi.org/10.1161/01.cir.98.9.839.

    Article  CAS  PubMed  Google Scholar 

  • Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836–43. https://doi.org/10.1056/NEJM200003233421202.

    Article  CAS  PubMed  Google Scholar 

  • Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr, Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001a;344(26):1959–65. https://doi.org/10.1056/NEJM200106283442601.

    Article  CAS  PubMed  Google Scholar 

  • Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001b;285(19):2481–5. https://doi.org/10.1001/jama.285.19.2481.

    Article  CAS  PubMed  Google Scholar 

  • Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20):1557–65. https://doi.org/10.1056/NEJMoa021993.

    Article  CAS  PubMed  Google Scholar 

  • Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation. 2004;109(23):2818–25. https://doi.org/10.1161/01.CIR.0000132467.45278.59.

    Article  CAS  PubMed  Google Scholar 

  • Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20–8. https://doi.org/10.1056/NEJMoa042378.

    Article  CAS  PubMed  Google Scholar 

  • Ridker P, Rifai N, Koenig W, Blumenthal RS. C-reactive protein and cardiovascular risk in the Framingham Study. Arch Intern Med. 2006;166(12):1327–8.; ; author reply 1328. https://doi.org/10.1001/archinte.166.12.1327-b.

    Article  PubMed  Google Scholar 

  • Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297(6):611–9. https://doi.org/10.1001/jama.297.6.611. Erratum in: JAMA. 2007;297(13):1433

    Article  CAS  PubMed  Google Scholar 

  • Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207. https://doi.org/10.1056/NEJMoa0807646.

    Article  CAS  PubMed  Google Scholar 

  • Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670):1175–82. https://doi.org/10.1016/S0140-6736(09)60447-5.

    Article  CAS  PubMed  Google Scholar 

  • Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017a;377(12):1119–31. https://doi.org/10.1056/NEJMoa1707914.

    Article  CAS  PubMed  Google Scholar 

  • Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, JJP K, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC, SPIRE Cardiovascular Outcome Investigators. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017b;376(16):1527–39. https://doi.org/10.1056/NEJMoa1701488.

    Article  CAS  PubMed  Google Scholar 

  • Ridker PM, Koenig W, Kastelein JJ, Mach F, Lüscher TF. Has the time finally come to measure hsCRP universally in primary and secondary cardiovascular prevention? Eur Heart J. 2018a;39(46):4109–11. https://doi.org/10.1093/eurheartj/ehy723.

    Article  CAS  PubMed  Google Scholar 

  • Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ, CANTOS Trial Group. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018b;391(10118):319–28. https://doi.org/10.1016/S0140-6736(17)32814-3.

    Article  CAS  PubMed  Google Scholar 

  • Ridker PM, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, Koenig W, Shimokawa H, Everett BM, Glynn RJ. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018c;39(38):3499–507. https://doi.org/10.1093/eurheartj/ehy310.

    Article  CAS  PubMed  Google Scholar 

  • Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, Mam V, Hasan A, Rosenberg Y, Iturriaga E, Gupta M, Tsigoulis M, Verma S, Clearfield M, Libby P, Goldhaber SZ, Seagle R, Ofori C, Saklayen M, Butman S, Singh N, Le May M, Bertrand O, Johnston J, Paynter NP, Glynn RJ, CIRT Investigators. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380(8):752–62. https://doi.org/10.1056/NEJMoa1809798.

    Article  CAS  PubMed  Google Scholar 

  • Ridker PM, MacFadyen JG, Glynn RJ, Bradwin G, Hasan AA, Rifai N. Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial. Eur Heart J. 2020;41(31):2952–61. https://doi.org/10.1093/eurheartj/ehaa160.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald E. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002;105(15):1760–3. https://doi.org/10.1161/01.cir.0000015464.18023.0a.

    Article  CAS  PubMed  Google Scholar 

  • Sattar N, Murray HM, McConnachie A, Blauw GJ, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Murphy MB, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, Shepherd J, PROSPER Study Group. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation. 2007;115(8):981–9. https://doi.org/10.1161/CIRCULATIONAHA.106.643114.

    Article  CAS  PubMed  Google Scholar 

  • Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, GT MI, Mehlsen J, Nieminen M, O’Brien E, Ostergren J, ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149–58. https://doi.org/10.1016/S0140-6736(03)12948-0.

    Article  CAS  PubMed  Google Scholar 

  • Shah B, Pillinger M, Zhong H, Cronstein B, Xia Y, Lorin JD, Smilowitz NR, Feit F, Ratnapala N, Keller NM, Katz SD. Effects of acute colchicine administration prior to percutaneous coronary intervention: COLCHICINE-PCI randomized trial. Circ Cardiovasc Interv. 2020;13(4):e008717. https://doi.org/10.1161/CIRCINTERVENTIONS.119.008717.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301–7. https://doi.org/10.1056/NEJM199511163332001.

    Article  CAS  PubMed  Google Scholar 

  • Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889–934. https://doi.org/10.1016/j.jacc.2013.11.002. Erratum in: J Am Coll Cardiol. 2014;63(25 Pt B):3024-3025. Erratum in: J Am Coll Cardiol. 2015;66(24):2812.

    Article  PubMed  Google Scholar 

  • Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, López-Sendón J, Ostadal P, Koenig W, Angoulvant D, Grégoire JC, Lavoie MA, Dubé MP, Rhainds D, Provencher M, Blondeau L, Orfanos A, L’Allier PL, Guertin MC, Roubille F. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–505. https://doi.org/10.1056/NEJMoa1912388.

    Article  CAS  PubMed  Google Scholar 

  • Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med. 1930;52(4):561–71. https://doi.org/10.1084/jem.52.4.561\.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, Meilahn EN, Kuller LH. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997;17(6):1121–7. https://doi.org/10.1161/01.atv.17.6.1121.

    Article  CAS  PubMed  Google Scholar 

  • U.S. Preventive Services Task Force. Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151(7):474–82. https://doi.org/10.7326/0003-4819-151-7-200910060-00008.

    Article  Google Scholar 

  • Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282(22):2131–5. https://doi.org/10.1001/jama.282.22.2131.

    Article  CAS  PubMed  Google Scholar 

  • Westlake SL, Colebatch AN, Baird J, Kiely P, Quinn M, Choy E, Ostor AJ, Edwards CJ. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford). 2010;49(2):295–307. https://doi.org/10.1093/rheumatology/kep366.

    Article  CAS  Google Scholar 

  • Wilson PW, Nam BH, Pencina M, D’Agostino RB Sr, Benjamin EJ, O’Donnell CJ. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med. 2005;165(21):2473–8. https://doi.org/10.1001/archinte.165.21.2473.

    Article  CAS  PubMed  Google Scholar 

  • de Winter RJ, Heyde GS, Koch KT, Fischer J, van Straalen JP, Bax M, Schotborgh CE, Mulder KJ, Sanders GT, Piek JJ, Tijssen JG. The prognostic value of pre-procedural plasma C-reactive protein in patients undergoing elective coronary angioplasty. Eur Heart J. 2002;23(12):960–6. https://doi.org/10.1053/euhj.2001.2988.

    Article  CAS  PubMed  Google Scholar 

  • Woloshin S, Schwartz LM. Distribution of C-reactive protein values in the United States. N Engl J Med. 2005;352(15):1611–3. https://doi.org/10.1056/NEJM200504143521525.

    Article  CAS  PubMed  Google Scholar 

  • Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O’Leary D, Carr JJ, Goff DC, Greenland P, Herrington DM. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012;308(8):788–95. https://doi.org/10.1001/jama.2012.9624.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yousuf O, Mohanty BD, Martin SS, Joshi PH, Blaha MJ, Nasir K, Blumenthal RS, Budoff MJ. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? J Am Coll Cardiol. 2013;62(5):397–408. https://doi.org/10.1016/j.jacc.2013.05.016.

    Article  CAS  PubMed  Google Scholar 

  • Zebrack JS, Anderson JL, Maycock CA, Horne BD, Bair TL, Muhlestein JB, Intermountain Heart Collaborative (IHC) Study Group. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol. 2002;89(2):145–9. https://doi.org/10.1016/s0002-9149(01)02190-7.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ciccarone Center for the Prevention of Cardiovascular Disease, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, USA

    David I. Feldman

  2. Ciccarone Center for the Prevention of Cardiovascular Disease, Department of Cardiology, The Johns Hopkins Hospital, Baltimore, MD, USA

    Roger S. Blumenthal

  3. Center for Cardiovascular Analytics, Research and Data Science (CARDS), Providence Heart Institute, Providence St. Joseph Health, Portland, OR, USA

    Ty J. Gluckman

Authors
  1. David I. Feldman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roger S. Blumenthal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ty J. Gluckman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ty J. Gluckman .

Editor information

Editors and Affiliations

  1. Section on Cardiovascular Disease, Wake Forest University School of Medicine, Winston Salem, NC, USA

    Michael D. Shapiro

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Feldman, D.I., Blumenthal, R.S., Gluckman, T.J. (2022). High-Sensitivity C-Reactive Protein. In: Shapiro, M.D. (eds) Cardiovascular Risk Assessment in Primary Prevention. Contemporary Cardiology. Humana, Cham. https://doi.org/10.1007/978-3-030-98824-1_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-98824-1_17

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-98823-4

  • Online ISBN: 978-3-030-98824-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation